Background: Cervical cancer, in women, is the second most common cancer world wide, next to breast cancer. During the treatment of carcinoma cervix, anemia is selectively frequent and its origin is complex combining hemorrhage, iron deprivation, inflammatory reactions and infection. The objective of this study is to evaluate the role of epoetin in correction of anemia and on treatment outcomes in patients with advanced cervical cancer receiving concurrent chemoradiotherapy.Results: A total of 120 patients were enrolled in the study of which 60 patients were randomized to receive epoetin beta in the treatment arm and 60 patients were in control arm where epoetin beta was not given. Total two and three patients absconded during treatment from treatment and control arm respectively; therefore total evaluable patients were 115. Mean Hb at baseline in the control arm was 10.70 g/dl ± 0.62 g/dl and 10.45 g/dl ± 0.43 g/ dl in the treatment arm (p > 0.05). At the end of treatment period mean Hb increased by 1.55 g/dl in patients receiving epoetin beta (p < 0.01), but decreased by 1.50 g/dl in the control arm (p < 0.01).There was significant reduction in blood transfusion in patients receiving epoetin beta (p < 0.01). At the end of treatment there was significant improvement in energy level, activity level and overall quality of life in the treatment arm (p < 0.01).There was no significant difference in overall survival (p > 0.05), or disease free survival (p > 0.05) between the two study arms. Adverse events were well matched between the two study arms. No Thromboembolic events associated with epoetin beta was observed in our study.Material and methods: Total 120, stage IIB to IIIB cervical cancer patients, aged 18-70 years with 9.50-12.50 gm/dl baseline Hb value who were to receive radiotherapy together with cisplatin were randomized to receive either epoetin beta 10,000 IU thrice weekly and oral iron starting 10-15 days before their 5-week course of whole pelvic irradiation and weekly cisplatin (treatment arm) or standard supportive care (control arm), where epoetin beta was not given.Blood transfusion was given in patients of both the arms if hemoglobin was ≤10 gm/dl.Conclusions: Treatment with epoetin beta safely and effectively corrects anemia in patients with advanced cervical cancer receiving chemoradiotherapy and is not associated with adverse effects on response rate, overall survival, disease free survival and chemoradiotherapy related acute and late toxicities.

Lymphocyte-predominant Hodgkin disease is a rare form of Hodgkin lymphoma that is recognized as a separate histopathological entity. This disease tends to have multiple relapses, but has an overall good prognosis. Owing to its rarity, and the prolonged time period between recurrence and transformation events, there is no consensus regarding optimal management. However, the National Comprehensive Cancer Network guidelines indicate that for early stages, appropriate treatment is radiotherapy. Several management options have been reported including observation, radiation, chemotherapy, combined chemoradiotherapy, and anti-CD20 antibody therapy. Salvage therapy remains effective in inducing prolonged remission in patients with relapsed/refractory disease.

No abstract

The landscape of treatment for metastatic castration-resistant prostate cancer has rapidly evolved during the last 5 years alone. In this review, standard therapies as well as recent advances in the systemic treatment for prostate cancer are explored. Pivotal trial data are summarized with emphasis on indications for various anti-androgen drugs, androgen-biosynthesis inhibitors, chemotherapy, immunotherapy and bone-targeted agents. The clinical, biochemical and radiographic outcomes for men with metastatic castration-resistant prostate cancer are improving with the establishment of several promising novel agents.